CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell Frequencies G Gulden, B Sert, T Teymur, Y Ay, NN Tiryaki, AK Mishra, E Ovali, ... Vaccines 11 (2), 313, 2023 | 4 | 2023 |
Exon7 Targeted CRISPR-Prime Editing Approaches for SMN2 Gene Editing in Spinal Muscular Atrophy (SMA) Disease Can Increase In Vitro SMN Expression SP Odabas, E Bal, G Yelgen, AS Metin, E Karakaya, G Gulden, B Sert, ... bioRxiv, 2022.03. 21.484406, 2022 | 1 | 2022 |
The Effect Of Molecular Genetic Mechanisms On Drug Addiction And Related New Generation CRISPR Gene Engineering Applications E Akyürek, B Uysal, G Gülden, C Taştan Gene 2, 50-60, 2021 | 1 | 2021 |
Development of DNA Ink & DNA Barcoding Technology on Practical Tracking & Authenticity Detection of Pharmaceutical Ingredients B Budaklar, B Sert, G Gülden, C Taştan | 1 | |
Sensitization of The Antibiotic Resistant M. smegmatis Bacteria Using CRISPR/FnCpf1 Gene Editing H Araz, G Gulden, B Sert, C Taştan Gene Editing 1 (4), 1-13, 2023 | | 2023 |
Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model B Sert, G Gulden, T Teymur, Y Ay, RD Turan, OM Unaldi, E Guzenge, ... Cancer Gene Therapy, 1-10, 2023 | | 2023 |
Increasing the Potency of CAR-T Cells by Phytohemagglutinin Activation in the In Vivo Acute Lymphoblastic Leukemia Model for Lasting Effect G Gulden, B Sert, T Teymur, Y Ay, RD Turan, C Tastan BIO Türkiye - International Biotechnology Congress, 2023 | | 2023 |
Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors D Sahan Khankishiyev, G Gulden, B Sert, C Tastan Current Tissue Microenvironment Reports 4 (1), 1-16, 2023 | | 2023 |
Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic Leukemia B Sert, G Gulden, T Teymur, Y Ay, RD Turan, OM Unaldi, E Guzenge, ... bioRxiv, 2023.07. 15.547808, 2023 | | 2023 |
The CRISPR-Cas12 SHERLOCK System Can Identify HIV CC Inci, G Gulden, B Sert, C Tastan Gene Editing, 14-18, 2022 | | 2022 |
In-vitro Investigation of Proliferation, Differentiation and Survival Capacity of Mesenchymal Stem Cells, Cancer and Lymphocytes in an Acoustic Levitation Device Providing … C Tastan, B Tekirdagli, E Cam, O Demir, B Sert, G Gulden 44th COSPAR Scientific Assembly. Held 16-24 July 44, 2855, 2022 | | 2022 |
Exon7 Targeted CRISPR-Prime Editing Approaches for SMN2 Gene Editing in Spinal Muscular Atrophy CT G. Yelgen, E. Bal, S.P. Odabas, F.N. Erkek, G. Gulden, B. Sert, T. Teymur ... 11th European Conference on Rare Diseases & Orphan Products - Poster …, 2022 | | 2022 |
CAR-T Cells with Phytohemagglutinin (PHA) Provide Anti-Cancer Capacity with Better Proliferation, Rejuvenated Effector Memory, and Reduced Exhausted T Cell Frequencies G Gulden, B Sert, T Teymur, Y Ay, NN Tiryaki, E Ovali, N Tarhan, C Tastan bioRxiv, 2022 | | 2022 |
Autonomous Remotely Controlled Closed System Transgenic Cell Technologies Robot: CRISPR. BOT (preprint) F Erkek, G Gulden, B Sert, MC Yilmaz, SP Odabas, E Bal, G Yelgen, ... | | 2022 |
Development of monoclonal antibodies against SARS CoV-2 spike protein antigens to use in diagnosis and therapy G Kılıç, IG Polat, GG Dinç, G Yılmaz, E Güzar, G Gülden, A Saygılı, ... European Journal of Immunology 51, 372, 2021 | | 2021 |
Nadir Hastalıkların Tedavisinde Gen Terapisi MEK Cihan Taştan, Yasemin Kartal, Gamze Gülden Tüm Yönleriyle Nadir Hastalıklar 1, 283-296, 2019 | | 2019 |
TÜM YÖNLERİYLE NADİR HASTALIKLAR Ö İnce, MD Pak | | 2019 |
Nadir Hastalıkların Tedavisinde Gen Terapisi C TAŞTAN, Y KARTAL, G Gülden, M Köse Nobel, 2019 | | 2019 |
The Effect Of Beta-Lactam-Containing Drugs On The Development Of Drug Allergy D Bakaçhan, B Sert, MK Zelka, G Gulden, C Tastan | | |
Expression of Axolotl P53 Gene May Increase Cancer Resistance HA Babar, Ö Kılıç, G Gülden, B Sert, C Taştan | | |